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1 These authors equally contributed to the paper.Protein phosphatase-2A (PP2A) activity is signiﬁcantly suppressed in Alzheimer’s disease. We have
reported that glycogen synthase kinase-3b (GSK-3b) inhibits PP2A via upregulating the phosphory-
lation of PP2A catalytic subunit (PP2AC). Here we studied the effects of GSK-3b on the inhibitory
demethylation of PP2A at leucine-309 (dmL309-PP2AC). We found that GSK-3b regulates dmL309-
PP2AC level by regulating PME-1 and PPMT1. Knockdown of PME-1 or PPMT1 eliminated the effects
of GSK-3b on PP2AC. GSK-3 could negatively regulate PP2A regulatory subunit protein level. We con-
clude that GSK-3b can inhibit PP2A by increasing the inhibitory L309-demethylation involving
upregulation of PME-1 and inhibition of PPMT1.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [3,4]. In addition, a unique type of reversible methylation occursThe activity of protein phosphatase 2A (PP2A) is signiﬁcantly
decreased in the brain of Alzheimer’s disease (AD). PP2A, one of
the four major classes (PP1, PP2A, PP2B and PP2C) of eukaryotic
serine/threonine phosphoprotein phosphatases [1,2], exists as a
number of holoenzymes. The core enzyme consists of a 36 kDa cat-
alytic subunit (PP2AC), and a 65 kDa scaffold subunit (A subunit).
PP2AC consists of 309 amino acids and is subjected to posttransla-
tional modiﬁcations. The C-terminal portion of PP2AC is highly con-
served among eukaryotes and is postulated to regulate PP2A
activity based on posttranslational modiﬁcation of its terminus.
For example, tyrosine kinases phosphorylate the tyrosine at posi-
tion 307, which reportedly inhibits PP2A phosphatase activitychemical Societies. Published by E
-3b; PP2A, protein phospha-
regulatory subunit; pY307,
rosine-307; dmL309-PP2AC,
09; AD, Alzheimer’s disease;
protein phosphatase methy-
P response element binding
; SB, SB216763; SD, Sprague–
cence
Liu).at the carboxy-terminal leucine-309 (Leu309) in a conserved
TPDYFL309 motif of PP2AC [5].
Glycogen synthase kinase-3b (GSK-3b) and PP2A are respec-
tively the most implicated protein kinase and protein phosphatase
in Alzheimer-like tau hyperphosphorylation [6,7]. The activity of
GSK-3b is stimulated [8,9] while the activity of PP2A is inhibited
in the AD brains [10,11]. Both acute and chronic administration
of lithium, a general inhibitor of GSK-3, signiﬁcantly increased
PP2A activity in frontal cortex and hippocampus of rats [12]. Treat-
ment of N2a cells with lactacystin, a proteasome inhibitor, caused
accumulation of the hyperphosphorylated tau with a concurrent
activation of GSK-3 and inhibition of PP2A [13]. It was also re-
ported that GSK3b activity increased in PP2A PR61/B0d (B56d)
knockout mice [14]. GSK-3b was associated with I2PP2A, an endog-
enously produced inhibitory protein of PP2A. Further studies dem-
onstrated that GSK-3b could regulate the expression of I2PP2A, at
the post-transcription level and thus control the activity of PP2A
and phosphorylation of tau protein [15]. These studies suggest a
mutual regulation of GSK-3b and PP2A.
In addition to the expression level, PP2A activity is also regu-
lated by posttranslational modiﬁcations, such as phosphorylation
at tyrosine-307 and methylation at leucine-309 [3,4,16]. In a recent
study, we reported that activation of GSK-3b increased the inhibi-
tory phosphorylation of PP2AC at Tyr307 by PTP1B and decreasedlsevier B.V. All rights reserved.
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further investigated whether GSK-3b also affects the inhibitory
demethylation of PP2A and the underlying mechanisms. We found
that activation of GSK-3b increased PP2A demethylation at leu-
cine-309 through inhibiting leucine carboxylmethyltransferase 1
(PPMT1) and upregulating protein phosphatase methylesterase
(PME-1).
2. Materials and methods
2.1. Plasmids
A plasmid expressing HA-tagged wild type GSK-3b (wtGSK-3b)
and GSK-3b+/ mice were kind gifts from Dr. James R. Woodgett of
Samuel Lunenfeld Research Institute (University of Toronto). pSi-
lencer plasmid was purchased from GeneChem Co., Ltd (Shanghai,
China), and sequences of PPMT1 (50-GGCAUGGAUACCACCU
UCUGGAGAU-30) [18], PME-1 (50-GGUACAGCUAUGGAUGCAC-30)
[19] were selected to generate pSilencer constructs that produce
small hairpin RNA (shRNA), which was then spontaneously pro-
cessed in vivo into siRNA. Lentivirus overexpression of GSK-3b
was purchased from GeneChem Co., Ltd (Shanghai, China).Fig. 1. Activation of GSK-3b increases dmL309 in vitro. HEK293 and N2a cells were treated
(7 lM) (WO (2 lM)+SB) for 1 h (C), or HEK293 cells were transfected with HA-tagged wil
leucine-309 (dmL309) was estimated by Western blotting and quantitative analysis. D
means ± S.D. of three independent experiments; ⁄, p < 0.05, ⁄⁄, p < 0.01 vs control (Ctl) o2.2. RT-PCR
Total RNA was isolated using TrizolTM according to the
manufacturer’s instruction (Invitrogen, CA). Then total RNA was
reversely transcribed and the produced cDNA was used to detect
the transcripts. For PPMT1, the following primers were used:
50-CATGGGTGATCGGTTTGG-30 (forward primer) and 50-TCCTCCTTT
GGTTGC-30 (reverse primer). For PME-1, the following primers
were used: 50-TCAAATGTCTTCCCAGGCTCAG-30 (forward primer)
and 50-CCACCGCTCGCTATGGCTAA-30 (reverse primer). For GAPDH,
50-GAAGGTGAAGGTCGGAGTC-30 (forward primer) and 50-GAA-
GATGGTGATGGGATTTC-30 (reverse primer) were used. The PCR
products were separated on 1.5% agarose gels and stained with
GoldView. The cDNA bands were visualized under UV transillumi-
nation and quantitatively analyzed using software BioCaptMW
V.10 (Vilber Lourmat, Marne-La-Vallee Cedex 1).
2.3. Lentivirus injection
For brain injection of the virus, 3-month-old C57micewere anes-
thetized with 6% chloralhydrate (0.6 ml/100 g) via intraperitoneal
injection, then positioned in a stereotaxic instrument and 2 ll len-respectively with wortmannin (WO) (A) or SB216763 (SB) (B) or WO (2 lM) plus SB
d type GSK-3b plasmid (wtGSK-3b) for 24 h (D). The level of PP2AC demethylated at
M1A to tubulin was used as a loading control (A–D). The data were presented as
r pcDNA; #, p < 0.05, ##, p < 0.01 vs WO (1 lM) or SB (5 lM).
Fig. 3. Wortmannin activates GSK-3b in vitro and in vivo. HEK293 cells were
treated, respectively with wortmannin (WO) (A), or wortmannin (WO) (B) was
infused into the lateral ventricle of 3-month-old SD rats, and then the levels of pS9-
GSK-3b (pS9) and GSK-3b in cell and hippocampus extracts were estimated by
Western blotting and quantitative analysis. DM1A to tubulin was used as a loading
control (A–B). The data were presented as means ± S.D. of three independent
experiments; ⁄, p < 0.05, ⁄⁄, p < 0.01 vs control (Ctl); ##, p < 0.01 vs WO (1 lM).
2524 X.-Q. Yao et al. / FEBS Letters 586 (2012) 2522–2528ti-wtGSK-3b or lenti-eGFP were injected into the hippocampus (AP
2.0, ML 1.5, DV 2.0) [20] at a rate of 0.50 ll/min. SB216763
(SB) or wortmannin (WO) was injected into the lateral ventricle
(AP 0.8, ML 1.5, DV 4.0) of 3-month-old SD rats. The syringe
was left in place for 3 min before being slowly withdrawn from
the brain. The animal experiments were carried out according to
the ‘‘Policies on theUse of Animals andHumans in Neuroscience Re-
search’’ approved by the Society for Neuroscience in 1995; and
supervised by Animal Administration and Ethics Committee of Ton-
gjiMedical College,HuazhongUniversity of Science andTechnology.
2.4. Western blotting and immunohistochemistry
Western blotting and immunohistochemistry were performed
according to methods established in our laboratory [17]. The anti-
bodies and regents used in the study see Supplementary data.
2.5. Statistical analysis
Data were analyzed with SPSS 13.0 statistical software. The
one-way analysis of variance procedure followed by least signiﬁ-
cant difference post hoc tests was used to determine the statistical
signiﬁcance of differences of the means.
3. Results
3.1. Activation of GSK-3b increases PP2A demethylation level both
in vitro and in vivo
To explore the effects of GSK-3b on PP2A demethylation, we
ﬁrst manipulated GSK-3 activity by treating the HEK293 and N2aFig. 2. Activation of GSK-3b increases dmL309 in vivo. Wortmannin (WO) (A), or SB216
lateral ventricle of 3-month-old SD rats, and then the level of dmL309 in hippocampus
type GSK-3b (lenti-wtGSK-3b) or the control (lenti-eGFP) was infused into the hippocamp
CA3 region of hippocampus was detected by immunohistochemistry (D), so: stratum orien
dmL309 was estimated by Western blotting in GSK-3b+/ mice (4-month-old) (E). DM
means ± S.D. of three independent experiments; ⁄, p < 0.05, ⁄⁄, p < 0.01 vs control (Ctl) ocells with GSK-3 activator (wortmannin, WO) or a speciﬁc inhibitor
(SB216763, SB), or WO plus SB for 1 h, and then measured the
inhibitory demethylation of PP2A at leucine-309 (dmL309) and
the total level of PP2AC. The activation or inhibition of GSK-3b
activity by WO or SB was conﬁrmed by a 32P-labeling assay [15]
or an inhibitory phosphorylated at serine 9 of GSK-3b [17]. We763 (SB) (B), or WO (100 lM) plus SB (70 lM) (WO + SB) (C) were infused into the
extracts was estimated by Western blotting (A–C). The eGFP-labeled lentiviral wild
al CA3 region of C57BL/6J (C57) mice (2 ll each). After 4 weeks, dmL309 level in the
s, sp: stratum pyramidale, sl: stratum lucidum, L: lateral and M: medial. The level of
1A to tubulin was used as a loading control (A–C, E). The data were presented as
r wild-type mice (wt).
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dmL309 with a decreased total PP2AC with an increased ratio of
dmL309/PP2AC, whereas inhibition of GSK-3 by SB restored PP2A
levels, and simultaneous inhibition of GSK-3 by SB prevented the
WO-induced PP2A inactivation (Fig. 1A–C). To conﬁrm the role of
GSK-3b on the demethylation of PP2AC, the wild type GSK-3b
(wtGSK-3b) plasmids and its control vector (pcDNA) were transfec-
ted into the HEK293 cells for 48 h by Lipofectamin, then, we found
that overexpression of GSK-3b also signiﬁcantly increased the level
of dmL309/PP2AC (Fig. 1D). These in vitro data suggest activation ofFig. 4. Activation of GSK-3b decreases PPMT1 and increases PME-1 both in vitro and in vi
treated as described in Fig. 1 and Fig. 2, and the levels of PPMT1 and PME-1 were esti
means ± S.D. of three independent experiments; ⁄, p < 0.05, ⁄⁄, p < 0.01 vs control (Ctl), pGSK-3b inhibits PP2A by increasing its demethylation at leucine-
309.
To verify the in vivo effect of GSK-3b on PP2A, we ﬁrst infused
WO, or SB, or WO plus SB into the lateral ventricle of 3-month-
old rats, and measured the levels of dmL309 at 24 h after the infu-
sion. We observed that activation of GSK-3 by WO increased the
inhibitory demethylation of PP2A, whereas inhibition of GSK-3
by SB restored the level of dmL309-PP2A in the rats, and simulta-
neous inhibition of GSK-3 by SB prevented the WO-induced PP2A
inactivation (Fig. 2A–C). To conﬁrm the in vivo role of GSK-3b, wevo. The cells (A–C, G), the SD rats (D–F) and GSK-3b+/ mice (4-month-old) (H) were
mated by Western blotting and quantitative analysis. The data were presented as
cDNA or wild-type mice (wt); #, p < 0.05, ##, p < 0.01 vs WO (1 lM) or SB (5 lM).
Fig. 6. GSK-3b increases PME-1 transcription and inhibits PPMT1 transcription.
HEK293 cells were treated with wortmannin (WO, 2 lM) or SB216763 (SB, 7 lM) or
WO (2 lM) plus SB (7 lM) (WO + SB) for 1 h, then the mRNA levels of PME-1 and
PPMT1 was detected by quantitative RT-PCR with GAPDH as a loading control. The
data were presented as means ± S.D. of three independent experiments; ⁄⁄, p < 0.01
vs control (Ctl); ##, p < 0.01 vs WO; DD, p < 0.01 vs SB.
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hippocampus of C57 mice. We found that overexpression of GSK-
3b increased dmL309 (Fig. 2D), whereas the level of dmL309-
PP2A was reversed in GSK-3b+/ mice (Fig. 2E). These in vivo data
further conﬁrm that GSK-3b affects PP2A activity by regulating
the leucine-309 demethylation. The level of t-GSK-3b did not
change, whereas the level of pS9-GSK-3b decreased both in vitro
(HEK293 cells) and in vivo (SD rats) after administration of WO
(Fig. 3), which conﬁrm the activation of GSK-3b by WO.
3.2. Activation of GSK-3b increases dmL309-PP2A through activating
PME-1 and inhibiting PPMT1
To investigate the mechanisms of GSK-3b regulating leucine-
309 demethylation of PP2A, we ﬁrst measured the protein levels
of PME-1 (a speciﬁc methylesterase) and PPMT1 (a speciﬁc leucine
carboxyl methyltransferase). We found that pharmacological acti-
vation of GSK-3 by WO increased PME-1 and decreased PPMT1
(Fig. 4A), whereas inhibition of GSK-3 by SB increased PPMT1
and decreased PME-1 (Fig. 4B); and simultaneous inhibition of
GSK-3 by SB reverted the WO-induced alterations of PPMT1 and
PME-1 in HEK293 and N2a cells, respectively (Fig. 4C). Similar re-
sults were also observed in rats infused with WO or SB (Fig. 4D–
F) and in HEK293 cell lines with genetic overexpression of
wtGSK-3b (Fig. 4G) or in GSK-3b+/ mice (Fig. 4H). These data dem-Fig. 5. Knockdown of PPMT1 or PME-1 by siRNA abolishes the effects of GSK-3 on
dmL309 of PP2AC. HEK293 cells were transfected with siPME-1 or siPPMT1 or the
scrambled controls (ssiPME-1 or ssiPPMT1) for 48 h (A,B), or combined with
treatment of wortmannin (WO, 2 lM) or SB216763 (SB, 7 lM) for 1 h (C,D). The
levels of dmL309, PME-1 and PPMT1 were measured by Western blotting and
quantitative analysis. DM1A to tubulin was used as a loading control. The data were
presented as means ± S.D. of three independent experiments; ⁄⁄, p < 0.01 vs ssiPME-
1, ssiPPMT1, ssiPME-1 +WO or ssiPPMT1 + SB.onstrate that GSK-3b can regulate both PPMT1 and PME-1 in pro-
tein levels, suggesting a potential role of PPMT1 and PME-1 in
mediating the effects of GSK-3b on PP2A methylation.
To conﬁrm the role of PME-1 and PPMT1, we used siRNA tech-
nique. Firstly, we found that PME-1 or PPMT1 level was decreased
by siRNA, respectively (Fig. 5A and B). Then, we observed that
knockdown of PME-1 downregulated the elevated dmL307-PP2A
level induced by GSK-3 activation (Fig. 5C), whereas knockdown
of PPMT1 with siRNA abolished the suppressed leucine-309
demethylation of PP2A induced by GSK-3 inhibition (Fig. 5D).
These results further conﬁrm that GSK-3 regulates demethylation
of PP2A at leucine-309 through regulating PME-1 and PPMT1.
3.3. GSK-3b regulates PPMT1 and PME mRNA expression
To explore whether GSK-3 affects the transcription of PPMT1
and PME-1, we measured the mRNA level by RT-PCR in HEK293
cells. We found that activation of GSK-3 by WO increased PME-1
and decreased PPMT1, whereas inhibition of GSK-3 by SB signiﬁ-
cantly decreased PME-1 and increased PPMT1 in mRNA levels,
and simultaneous inhibition of GSK-3 by SB reversed the WO-in-
duced changes of PME-1 and PPMT1 mRNA levels (Fig. 6). These
data together suggest that GSK-3bmay regulate PME-1 and PPMT1
through affecting the transcription.
3.4. Activation of GSK-3b decreases PP2A regulatory subunit in protein
level
We also detected PP2A regulatory subunit (B55 alpha) after
infusion of WO or SB into the lateral ventricle of 3-month-old rats
for 24 h (Fig. 7A and B), or treatment of HEK293 cells for 1 h
(Fig. 7C and D). We found that activation of GSK-3 by WO de-
creased the level of PP2AB in protein level, whereas inhibition of
GSK-3 by SB reversed the level of PP2AB both in vivo and in vitro
(Fig. 7A–D).
4. Discussion
AD is the most common type of dementia in the aged popula-
tion and is characterized pathologically by the presence of neuro-
ﬁbrillary tangles (NFTs) and senile plaque (SPs) [21]. Both NFTs
and the peripheral neuritis found in neuritic-type SPs consist of
Fig. 7. Activation of GSK-3b decreases PP2AB protein level. The SD rats (A–B), the
HEK293 cells (C–D) were treated as described in Fig. 1 and Fig. 2, and the level of
PP2AB was estimated by Western blotting and quantitative analysis. The data were
presented as means ± S.D. of three independent experiments; ⁄, p < 0.05, ⁄⁄, p < 0.01
vs control (Ctl).
X.-Q. Yao et al. / FEBS Letters 586 (2012) 2522–2528 2527hyperphosphorylated tau molecules. It has been well recognized
that there is an imbalance between the activities of tau-directed ki-
nases and phosphatases in the AD brains [22], and among various
kinases and phosphatases, GSK-3b [23,24] and PP2A [6,7,11,25] are
respectively the most implicated.
Efforts aimed at understanding PP2A regulation have uncovered
a complex set of non-covalent and covalent mechanisms. These in-
clude association with different regulatory subunits [1], associa-
tion with heat stable inhibitors [26], action of a phosphotyrosyl
activator protein [27], lipid binding [28], phosphorylation [3],
and methylation [29–32]. These mechanisms affect the catalytic
activity, substrate speciﬁcity, and cellular localization of PP2A.
The carboxyl terminus of the PP2A catalytic subunit seems to be
a focal point for regulation of PP2A. It is known that the inhibitory
posttranslational modiﬁcations, such as demethylation at leucine-
309 and phosphorylation at tyrosine-307, contribute to PP2A inhi-
bition [3,33,34]. Recently, we have reported that GSK-3b can regu-
late PP2A activity through regulating the activity-dependent
phosphorylation at tyrosine-307 [17]. In this study, we demon-
strate that upregulation of GSK-3b increases the inhibitory
demethylation of PP2A at leucine-309, whereas downregulation
of GSK-3b restores the leucine demethylation of PP2A, suggesting
that GSK-3b can also regulate PP2A activity through regulating
the activity-dependent demethylation of PP2A.
To explore the molecular mechanisms that may underlie the ef-
fects of GSK-3b on PP2A demethylation, we measured PPMT1, a
speciﬁc methyltransferase that can catalyze the methylation [35],
and PME-1, a speciﬁc methylesterase that can catalyze the
demethylation [36,37]. We found that both pharmacological and
genetic upregulation of GSK-3b increased the protein level of
PME-1 and decreased the protein level of PPMT1, and downregula-
tion of GSK-3b decreased PME-1 protein level and increased PPMT1
protein level. Furthermore knockdown of PME-1 by siRNA almost
abolished the effect of upregulation of GSK-3b on PP2A demethyl-
ation, and knockdown of PPMT1 by siRNA almost abolished the ef-
fect of downregulation of GSK-3b on PP2A methylation. These data
strongly suggest that GSK-3bmay regulate the leucine demethyla-
tion of PP2A through PPMT1 and PME-1. It is current not fully
understood how GSK-3b may affect PME-1 or PPMT1. GSK-3bmay inhibit PPMT1 transcription and promotion of PME-1 tran-
scription must be involved as demonstrated in the current study.
We also found that GSK-3b regulated PP2AB subunit protein level
and the mechanism needs further study. A recent study showed
that downregulation of PPMT1 led to B subunit downregulation
[38], suggesting that GSK-3b may regulate B subunit protein
expression by PPMT1. On the other hand, PME-1 also stably inter-
acts with an inactive PP2A form, which potentially independently
of an effect on PP2A demethylation [39,40]. In the AD brains, the
decreased PTP1B (protein tyrosine phosphatase 1B) activity [41],
the decreased PPMT1 protein expression, the decreased PP2AC
and PP2AB level [42], the upregulated I2PP2A level [43], the de-
creased PP2AC methylation levels [32] and the upregulated tyro-
sine phosphorylation of PP2A at tyrosine-307 [44] have also been
observed, which strongly support our observations.
Although activation of GSK-3b has not been consistently ob-
served in AD brain, the spatiotemporal distribution of active
GSK-3b in the AD brains coincides with the progression of NFTs
and neurodegeneration [45,46], and neurons undergoing granulo-
vascular degeneration also contain active GSK-3b [47]. Further-
more, the total level of GSK-3b protein is increased in the white
blood cells of both AD and MCI patients [8]. These studies provide
evidence that GSK-3b is upregulated in AD patients. Activation of
GSK-3b can inhibit PP2A through multiple mechanisms, including
accumulating PP2A endogenous inhibitor I2PP2A by hnRNP A18
[15], increasing pY307 by inhibiting PTP1B, decreasing PP2AC pro-
tein and mRNA level by CREB [17], reducing Leu309 methylation
by increasing PME-1 and decreasing PPMT1 protein levels, and
decreasing PP2AB protein level (Supplementary Fig. 1). Our data
strongly suggest that targeting the hyperactivated GSK-3b in the
AD brains could rescue the suppressed PP2A, which may represent
a powerful strategy in preventing tau hyperphosphorylation and
accumulation.
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